Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer

Phase 2 Recruiting 26 enrolled Pingping Song

NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, exploratory trial to evaluate the efficacy and safety of neoadjuvant WX-0593 in patients with resectable ALK-positive or ROS1- positive non-small cell lung cancer(NSCLC).

Timeline

Start: 2023-03-01
Primary completion: 2027-03
Completion: 2029-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	WX-0593	Small molecule	180 mg	—

Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer

Summary

Timeline

Drugs

Indications